‘Hope’ isn’t mere wishful thinking – it’s a valuable tool we can put to work in a crisis
Christian van Nieuwerburgh, University of East London The COVID-19 pandemic sweeping the world has prompted…
Author ONA Editor
ONA Editor
The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.
ESMO 2020: Immunotherapy is beneficial in gastric and oesophageal cancers
New data presented at ESMO 2020 have shown that immunotherapy is beneficial for patients with gastric and…
ESMO 2020: Two-pronged attack using new targeted drug could treat ‘addicted’ prostate cancers
An experimental cancer drug used alongside targeted hormone treatment could treat an aggressive group of…
ESMO 2020: Research breakthrough offers new hope for high risk patients with HR+ breast cancer
A new treatment for breast cancer patients with hormone receptor (HR+) early stage disease who…
ESMO 2020: Step forward in treatment for patients with newly diagnosed advanced ovarian cancer
Almost half of patients who received a targeted drug during treatment for newly diagnosed BRCA-mutated…
Mathematical model maps out ‘arms race’ between cancer and immune system and predicts effectiveness of immunotherapy
Researchers have created a mathematical model that can determine the impact of the immune system on tumour evolution.…
NSW introduces skin cancer prevention to school curriculum
School teachers in NSW can now harness a new suite of interactive skin cancer prevention…
ESMO 2020: Amivantamab with lazertinib in patients with EGFR-mutated non-small cell lung cancer
The CHRYSALIS study (NCT02609776) is evaluating amivantamab, a fully human bispecific antibody that targets epidermal…
ESMO 2020: No benefit for post-operative radiotherapy in non-small-cell lung cancer
Post-operative radiotherapy (PORT) used in patients with non-small-cell lung cancer (NSCLC) following complete resection and…
ESMO 2020: PARP inhibitor olaparib for the targeted treatment of metastatic prostate cancer
Results from the PROfound phase III study, funded by AstraZeneca and Merck Sharp & Dohme,…